Fujifilm launches a Medium-Term Management Plan, VISION2023
-Investing 1.2 trillion yen over three years to accelerate growth mainly in the healthcare and highly-functional material businesses
-Expanding the healthcare business into the largest segment in terms of revenue and operating income
TOKYO, April 15, 2021 – FUJIFILM Holdings Corporation (President: Kenji Sukeno) launched a new medium-term management plan, VISION2023, covering the period of three years from fiscal year ending March 2022 (FY2021) to FY2023. The VISION2023 foresees investments totaling 1.2 trillion yen over the three-year period to accelerate business growth with a focus on healthcare and highly-functional materials businesses. The healthcare business is to be expanded to the largest segment in terms of both revenue and operating income to build a robust business foundation that enables sustainable growth.
In FY2017, Fujifilm drew up the CSR plan, Sustainable Value Plan 2030 (SVP2030), setting out long-term goals to be achieved by the target year of FY2030. The SVP2030 sets out goals for four priority areas, namely “Environment,” “Health,” “Daily Life” and “Work Style,” as well as “Supply Chain” and “Governance,” which provides the base for business activities, from the perspective of “solving social issues through business activities” and “considering society and the environment in business processes” to contribute to establishing a sustainable society. The VISION2023 serves as a concrete action plan for realizing goals listed in the SVP2030.
The VISION2023 has the primary goals of accelerating business growth in healthcare and highly-functional materials and building more resilient business platform to facilitate sustainable growth. To this end, Fujifilm will promote four priority measures, (1) reinforcing business portfolio management, (2) strengthening cash flow management, (3) entering into new markets for further growth, (4) creating stronger integrated business synergies through M&A.
Under the VISION2023, each of the company’s business is positioned to the stages of “new / future potential”, “priority” and “earnings base”. Over the three-year period from FY2021 to FY2023, Fujifilm will make growth investments worth 1.2 trillion yen in total, including investments in R&D investments and capital expenditures in “new / future potential” and “priority” businesses in particular. An approach that emphasizes capital efficiency will be adopted to strengthen the ability to generate cash in order to create an operating cash flow of 1 trillion yen in cumulative total over three years. Fujifilm will continue to invest in categories where its technological strengths can be leveraged and create a synergistic effect through M&A.
These initiatives are to bring the revenue of 2.7 trillion yen in the plan’s final year of FY2023. The plan also foresees record profits, generating 260 billion yen in operating income and 200 billion yen in net income attributable to FUJIFILM Holdings, while developing healthcare into the company’s largest segment in terms of revenue and operating income during the VISION2023 period.
Ideal Vision
Using its leading-edge, proprietary technologies to provide top-quality products and services, Fujifilm will strive to resolve social issues through business activities and contribute to the realization of a sustainable society.
FY2030 targets set out in the SVP2030:
Overview of the medium-term management plan, VISION2023
1. Financial targets
2. Outlines and priority measures in the plan
The plan calls for securing active growth investments, concentrating management resources to “new / future potential” and “priority” businesses and accelerating / strengthening cash generation and investment cycle in order to accelerate growth in healthcare and highly-functional materials and build more resilient business platform to facilitate sustainable growth. Four priority measures are promoted to this end.
(1) Reinforcing business portfolio management
Reorganize business segments into Healthcare, Materials, Business Innovation and Imaging. Position each business in these segments to the stages of “new / potential”, “priority” and “earnings base”, and implement strategic measures in line with their respective business phases.
Over the three-year period from FY2021 to FY2023, Fujifilm will make growth investments worth 1.2 trillion yen in total, including R&D investments and capital expenditures in “new / potential” and “priority” businesses in particular.
(See 3 below for main measures for each of the segments.)
(3) Entering into new markets for further growth
Continue investing in fields where Fujifilm’s technological strengths can be leveraged, such as AI technology, biotechnology and photo regulation materials technology*1, as the company attempts to enter into new markets.
*1 Technology that realizes various optical characteristics by controlling light. It is used in polarizing plate protective films (Display materials) that can expand the viewing angle, and color resists for image sensors (Electronic Materials) that achieve high resolution, low noise, and faithful color reproduction.
(4) Creating stronger integrated business synergies through M&A
Generate integration benefits, such as synergy with FUJIFILM Healthcare, which took over Hitachi’s diagnostic imaging-related business, and acceleration of global operational presence and reinforcement of solution & services business by FUJIFILM Business Innovation.
3. Main measures for each segments
(1) Healthcare
Business fields
Medical Systems, Bio CDMO, Life Sciences (including regenerative medicine and drug discovery support such as cell culture media and reagent), Pharmaceutical Products, Consumer Healthcare (cosmetics and supplements)
FY2023 target
860 billion yen in revenue, 103 billion yen in operating income and 12.0% in operating margin
(2) Materials
Business fields
Electronic Materials, Display Materials, Fine Chemical, Industrial Products, Recording Media, Graphic communication, Inkjet
FY2023 target
720 billion yen in revenue, 95 billion yen in operating income and 13.2% in operating margin
(3) Business Innovation
Business fields
Office Solutions, Business Solutions
FY2023 target
820 billion yen in revenue, 82 billion yen in operating income and 10% in operating margin
* Stands for Small and Medium Business.
(4) Imaging
Business fields
Imaging Solutions
FY2023 target
300 billion yen in revenue, 25 billion yen in operating income and 8.3% in operating margin